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Penilaian Sifat Hipoglisemik Ekstrak Akueus Bunga Etlingera elatior pada 
Tikus yang Diabetes: Kajian Rintis  
ABSTRAK 
Diabetes mellitus (DM) merupakan gangguan metabolik yang bercirikan 
hiperglisemia yang berterusan, di mana jumlah glukosa terlebih beredar dalam darah. 
Di Malaysia, Etlingera elatior telah digunakan secara tradisional untuk mengurangkan 
kadar glukosa darah. Kajian rintis ini bertujuan untuk menilai sifat hipoglisemik 
ekstrak akueus bunga E. elatior (AEEFE) pada tikus Sprague Dawley (SD) diabetik 
yang diaruh dengan diet lemak-tinggi buatan-sendiri (HFD) dan streptozotocin (STZ). 
Kajian rintis ini terbahagi kepada dua fasa: induksi kegemukan (keadaan prediabetik) 
menggunakan HFD buatan sendiri dan induksi diabetes mellitus Jenis 2 (T2DM) 
menggunakan 30 mg/kg STZ. Oleh sebab Perintah Kawalan Pergerakan (PKP) yang 
dikuatkuasakan oleh kerajaan Malaysia terhadap kes pandemik Covid-19, hanya 
keputusan daripada bahagian pertama telah dianalisis. Indeks Jisim Badan (BMI) tikus 
SD mencapai kategori kegemukan setelah 4 minggu pemakanan HFD walaupun 
terdapat penurunan pengambilan makanan. Kadar glukosa darah dan tekanan darah 
sistolik (SBP) kumpulan eksperimen juga meningkat. Walaupun fasa kedua tidak 
dapat dilaksanakan kerana PKP, keputusan yang dijangkakan masih dilapor 
berdasarkan data dan maklumat daripada artikel yang telah diterbitkan. Kesan AEEFE 
dalam pemeriksaan biokimia dan histopatologi dijangkakan berkesan dalam 
pemulihan jika dibandingkan dengan kumpulan diabetes tidak terawat. Sebatian 
bioaktif yang terdapat dalam AEEFE seperti antosianin dan flavonoid dijangkakan 
dapat mengurangkan komplikasi daripada hiperglisemia dan meningkatkan kepekaan 
insulin. Oleh itu, semua hasil dapatan yang dijangkakan dalam kesan AEEFE, bunga 
E. elatior dijangka mempunyai potensi hipoglisemik dalam rawatan T2DM. 
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Evaluation on Hypoglycaemic Properties of Aqueous Etlingera elatior Flower 
Extract on Diabetic-Induced Rats: A Pilot Study 
ABSTRACT 
Diabetes mellitus (DM) is a metabolic disorder characterised by persistent 
hyperglycaemia, in which an excessive amount of glucose circulates in the blood. In 
Malaysia, Etlingera elatior has been used traditionally for reducing blood glucose 
levels. This pilot study was designed to evaluate the hypoglycaemic properties of 
aqueous E. elatior flower extract (AEEFE) on a self-made high-fat diet (HFD) and 
streptozotocin (STZ)-induced diabetic Sprague Dawley (SD) rats. There were 2 phases 
in the pilot study: induction of obesity (prediabetic state) using self-made HFD and 
induction of Type 2 diabetes mellitus (T2DM) using 30 mg/kg STZ. Due to the 
Movement Control Order (MCO) imposed by the Malaysian government because of 
the pandemic Covid-19 outbreak, only the results from the first part of the study had 
been analysed. The Body Mass Index (BMI) of the Sprague Dawley (SD) rats reached 
the obesity category after 4 weeks of HFD feeding despite there was a reduction of 
food intake. The blood glucose level and systolic blood pressure (SBP) of the 
experimental group were also increased. Although the second phase of the study 
cannot be continued due to MCO, the expected results were still being reported based 
on the data and information from the previously published articles. The effects of 
AEEFE in the biochemical and histopathological examinations were expected to 
exhibit improved results when compared to the untreated diabetic group. The bioactive 
compounds present in the AEEFE such as anthocyanin and flavonoid were expected 
to minimise the complications from hyperglycaemia and increase insulin sensitivity. 
Therefore, from all the evidence collected in the expected effects on AEEFE, E. elatior 





1.1 Background of Study 
Diabetes mellitus (DM) is a disorder characterised by persistent hyperglycaemia 
caused by insulin defect, insulin secretion or both (Ozougwu et al., 2013; ADA, 2020). 
There are three types of diabetes, Type 1 diabetes mellitus (T1DM), Type 2 diabetes 
mellitus (T2DM) and gestational diabetes. T2DM is the most common form of 
diabetes due to obesity, older age, and family history of the disease as risk factors 
(ADA, 2020). This disease has a very serious health effect and results in secondary 
complications, including cardiovascular, ocular, neurological and renal abnormalities 
that cause morbidity, disability and premature death in young adults. 
 
DM is a group of metabolic disorders that are characterized by hyperglycaemia. 
Dysfunction in carbohydrate, lipid and protein metabolism and insulin signalling 
defect leads to hyperglycaemia (ADA, 2020). This condition is associated with 
oxidative stress, which increases the formation of reactive oxygen species (ROS) and 
reduces antioxidant levels. Under oxidative stress, a highly toxic product is released, 
resulting in oxidative damage to the pancreas, liver and kidneys (Sharma et al., 2011). 
 
Nowadays, diabetes management is now focusing on the usage of medicinal plant 
because of their lower side effects compared to synthetic pharmaceutical drugs, which 
are more costly. In Malaysia, the flowers of E. elatior (bunga kantan) are traditionally 
used by the locals for food and medicinal purposes. They believed that daily intake of 
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raw inflorescence could reduce diabetes (Wijekoon et al., 2011). However, the effects 
of E. elatior flower extract on diabetes have not been scientifically well studied. 
 
The aim of this pilot study was therefore to evaluate the effects of anthocyanin-rich 
aqueous flower extract E. elatior as a potential antidiabetic agent and its mechanism 
in the T2DM rat model. 
 
The aqueous E. elatior flower extract (AEEFE) was prepared in this study using a 
sonication process at the School of Health Sciences, Universiti Sains Malaysia (USM) 
Kelantan. Sprague Dawley (SD) rats will be induced by streptozotocin (STZ) to 
become diabetic. The efficacy of the extract will be assessed against metformin, an 
oral hypoglycaemic agent (OHA) in subacute animal studies. Blood will be collected 
within and at the end of the animal study; subject to biochemical investigation and 
assessment of oxidative stress biomarkers. The rat organs will be subject to 
histopathological examination. 
 
1.2 Problem statement  
In Malaysia, E. elatior inflorescences are traditionally used by the locals for food 
flavouring and medicinal purposes. They believed that daily intake of raw 
inflorescence could reduce diabetes (Wijekoon et al., 2011). As of today, no such effort 
has been made to understand the mechanism of action of the crude AEEFE associated 
with the reduction of hyperglycaemic properties in in vivo systems and 





1.3 Rational of study 
Previous study has shown that the potential of E. elatior flower to reduce blood glucose 
level in T2DM rat model (Nor et al., 2019). As of this date, it remains to be assessed 
whether the flower has an effect on the reduction or prevention of an end-organ 
complication due to diabetes. In addition, the relationship between the E. elatior flower 
and the antioxidant properties also has an effect on diabetes that has yet to be clarified. 
This study is therefore proposed to evaluate the effects of AEEFE as a potential 
antidiabetic agent in the T2DM rat model. 
 
1.4 Study objectives 
1.4.1 General objective 
To evaluate the effects of anthocyanin-rich AEEFE in the T2DM rat model as a 
potential hypoglycaemic agent. 
 
1.4.2 Specific objectives 
1 To elucidate the effects of self-made HFD on the food intake, BMI, blood glucose, 
and blood pressure in the SD rats. 
2 To evaluate the effects of oral AEEFE on lowering blood glucose levels in 
diabetic-induced rats.  
3 To assess the effects of oral AEEFE on the lipid profile, liver and renal function 
tests in diabetic-induced rats.  
4 To determine the relationship between oral AEEFE and oxidative stress 
biomarkers in diabetic-induced rats.  





The hypothesis of the study are as follows： 
The AEEFE may has the hypoglycaemic properties on diabetic rat.  
Specifically,   
1. The oral AEEFE significantly lowers the blood glucose in diabetic-induced rats 
2. The oral AEEFE significantly improves on lipid profile, liver and renal 
function tests in diabetic-induced rat. 
3. The antioxidant biomarkers significantly improved with oral AEEFE. 
4. There is significant improvement of liver, kidney and pancreas structures in 
diabetic-induced rat. 
 
1.6 Significance of the Study 
Diabetes mellitus is a serious public health problem that has raised concerns around 
the world. Diabetes management is now focusing on the usage of medicinal plants 
because of their readily available, affordable and lower side effects compared to 
synthetic pharmaceutical drugs (Nasri, 2013; Nor et al., 2019). Results of this subacute 
analysis are therefore intended to clarify the possible antidiabetic effect of the E. 









2.1 Diabetes mellitus in general 
Diabetes mellitus (DM) is a group of metabolic and physiological disorders 
characterised by elevated blood glucose level or hyperglycaemia resulting from either 
impairment in the insulin secretion, resistance to insulin action or inadequate response 
to the insulin secretion in pancreas (ADA, 2020; CDC, 2020; WHO, 2020). Chronic 
hyperglycaemia leads to prolonged damage, dysfunction, and failure of various body 
systems particularly the blood vessels, eyes, heart, kidneys, and nerves (Asmat et al., 
2016; Tan et al., 2019). 
 
2.2 Epidemiology   
International Diabetes Federation (IDF) stated there are approximately 463 million 
adults aged 20-79 years were suffering from diabetes in 2019; and expected that this 
will rise to 700 million by 2045. Meanwhile, diabetes prevalence has been increasing 
rapidly in low- and middle-income countries.  Approximately 1 in 5 of those over 65 
years of age with diabetes and 1 in 2 (232 million) with diabetes worldwide have not 
been diagnosed. Diabetes is one of the top 10 causes of death in adults and is estimated 
to cause 4.2 million deaths worldwide in 2019. Global health expenditure on diabetes 
was estimated to be at least USD 760 billion in 2019, which was 10% of total adult 
spending. More than 1.1 million children and adolescents live with Type 1 diabetes 
mellitus (T1DM), while approximately 374 million people are at increased risk of 
developing Type 2 diabetes mellitus (T2DM). In addition, more than 20 million live 
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births, which accounts for approximately 1 in 6 live births, are affected by diabetes 
during pregnancy.  
 
In Malaysia, there is an alarming increase in the diabetes prevalence as reported by the 
National Health and Morbidity Survey (NHMS). The overall diabetes prevalence was 
18.3% in 2019, affecting 3.6 million individuals, with approximately 9.4% known 
diabetes and 8.9% raised blood glucose among unknown diabetes (IPH, 2020). A study 
in Malaysia found the highest prevalence of T2DM among Indians, followed by 
Malays and Chinese (Hussein et al., 2015). This growing chronic disease has obviously 
affected the nation productivity particularly would have negative impacts on the socio-
economic development in Malaysia.  
 
2.3 Types of diabetes mellitus 
The main categories of diabetes are type 1, type 2 and gestational diabetes mellitus. 
 
2.3.1 Type 1 diabetes mellitus 
Type 1 diabetes mellitus (T1DM) is generally considered as an autoimmune disorder 
and it represents only around 10% of the diabetes cases globally  (Katsarou et al., 2017; 
Paschou et al., 2018). Autoimmune disorders occur when the immune system attacks 
the body's own tissues and organs. The T-cells respond to the autoantigens and 
damages the pancreatic insulin-producing β-cells. Damage to these cells impairs 
insulin production and leads to the signs and symptoms of T1DM. Generally, insulin 
controls how much glucose is passed from the blood into cells for conversion to 
energy. Lack of insulin results in the inability to use glucose for energy or to control 
the amount of sugar in the blood.  
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Scientists believe that the majority of T1DM is influenced by hereditary genes, namely 
the human leukocyte antigen (HLA) types (Noble et al., 2010; Noble and Valdes, 2011; 
Richardson et al., 2016). HLA complex polymorphic alleles, which located on 
chromosome 6, are responsible for 40-50% of the genetic risk of T1DM pathogenesis.  
In addition, some studies have shown that T1DM can also be triggered by the 
environmental factors including low  vitamin D levels, lower exposure to ultraviolet 
rays, and viral infections (Coppieters et al., 2012; Craig et al., 2013; Beeck and Eizirik, 
2016).  
 
There is no cure for T1DM and the disease is progressing towards the complete 
destruction of β-cells of the pancreas. T1DM may occur at any age; but it usually 
develops at an early age, most of which begins in adolescence (Simmons, 2015; 
Stenberg, 2015; Katsarou et al., 2017). 
 
People with T1DM need lifelong treatments of daily insulin injections to manage their 
condition, which still leaves them at risk of long-term complications. The injected 
insulin is made up for the insulin that is not produced by the body. Most people with 
T1DM require two to four injections per day (Kahanovitz et al., 2017; Katsarou et al., 
2017). 
 
2.3.2 Type 2 diabetes mellitus 
Type 2 diabetes mellitus (T2DM) is a progressive health problem and accounts for 
around 90% of all diabetes cases worldwide (Toplak et al., 2016; WHO, 2020). 
Formerly known as non-insulin-dependent, or adult-onset,  T2DM happens as a result 
of dysregulation of carbohydrate, lipid and protein metabolism, and results from 
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hyperglycaemia, impaired of insulin resistance, insulin secretion, or a combination of 
both (Lin and Sun, 2010; Olokoba et al., 2012). 
 
T2DM is characterised by insulin insensitivity (Asghar and Sheikh, 2017; Czech, 
2017; Gaballah et al., 2017). Unlike people with T1DM, people with T2DM are 
making insulin. However, the body is becoming resistant to the normal effects of 
insulin, or is gradually losing the capacity to produce enough insulin in the pancreas. 
This condition makes the body unable to utilise the insulin effectively to maintain the 
glucose homeostasis over a long period of time.  
 
T2DM is most commonly seen in persons older than 45 years of age (Ginter, 2012; 
Chaudhury et al., 2017). However, it is increasingly seen in children, adolescents, and 
younger adults due to rising levels of alcohol consumption, cigarette smoking, family 
history, hypertension, obesity, overweight, physical inactivity, poor diets and 
sedentary lifestyle. 
 
Although there is yet no cure for the T2DM, it can be prevented through diet control, 
lifestyle modification, weight control. In addition, there are many medicines available 
in the market that have been approved by Food and Drug Association (FDA) to 







2.3.3 Gestational diabetes mellitus 
Gestational diabetes mellitus (GDM) is defined as hyperglycaemia with onset and first 
recognition between 24 to 28 weeks of gestation of a woman (Baynest, 2015; Kc et al., 
2015). Placental production of diabetogenic hormones such as human placental 
lactogen in late pregnancy, leading to progressive insulin resistance; when adaptation 
β-cell function during pregnancy fails to compensate for maternal insulin resistance, it 
may lead to gestational diabetes. In addition, some researchers believe that gestational 
diabetes is caused by the hormonal changes of pregnancy combined with genetic and 
lifestyle factors. Gaining too much weight during pregnancy can also be a factor. The 
condition caused by GDM is typically temporary. It usually resolves after childbirth, 
but it carries pre-, peri-, and postnatal risks of adverse outcomes in the mother and the 
offspring.  
 
As reported by IDF, about 7-10% of all pregnancies worldwide suffered from GDM. 
The vast majority of cases of hyperglycaemia during pregnancy have occurred in low- 
and middle-income countries, where access to maternal care is often limited 
(Behboudi-Gandevani et al., 2019). 
 
Gestational diabetes is diagnosed by prenatal screening, rather than through reported 
symptoms. Although GDM may occur anytime during pregnancy, it generally affects 
pregnant women during the second and third trimesters, and at delivery (Kc et al., 
2015; Mukerji et al., 2020).  
 
Women with gestational diabetes are at subsequent high risk of developing T2DM, 
particularly three to six years after delivery (Reece, 2010; Joham et al., 2014; Zhu et 
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al., 2019). In the meantime, exposure to hyperglycaemia in the womb predisposes 
offspring to a lifelong risk of becoming overweight or obese, due to the development 
of T2DM. 
 
It is important for pregnant women with diabetes or GDM to carefully control and 
monitor their blood glucose levels in order to reduce the risk of adverse pregnancy 
outcomes with the support of their healthcare provider (Kc et al., 2015; Shen et al., 
2019). GDM can usually be controlled through eating healthy foods and regular 
exercise (CDC, 2020). However, sometimes a woman with GDM must also take 
insulin to keep blood glucose under control. Table 2 summarised the comparison 

















Table 2.1: Comparison of T1DM, T2DM, and GDM (Adapted from Kommoju and 
Reddy, 2011; Heianza and Qi, 2017; Katsarou et al., 2017; Tan et al., 
2019; CDC, 2020)  
Features Type 1 Diabetes 
Mellitus (T1DM) 
 






Clinical • Young onset: <20 
years  





• Older onset: >30 
years, obese 






Prevalence • 5% of all cases • 90% of all cases • 7-10% of all 
pregnancies  
Risk factors • Genetic  
• Environmental 
• Age 






• Obesity  
Pathogenesis • Autoimmune 
destruction of 
pancreatic β-cells  
• Adipose tissue and 
liver 
• β-cells destruction  
• Insulin deficiency  
• Insulin resistance 






Treatment • Insulin for 
lifetime 
• Exercise  
• Healthy lifestyle 
• Insulin 
• Oral medicines  
• Healthy diet 
















2.4 Signs and symptoms 
The signs and symptoms of diabetes are caused by the increasing blood glucose level 
or hyperglycaemia. The classic symptoms of diabetes including polyuria (frequent 
urination), polydipsia (excessive thirst), polyphagia (extreme hunger), unusual weight 
loss, increased fatigue, irritability, blurry vision, pain or numbness of hands and legs 
(Kooti et al., 2016; Katsarou et al., 2017; Pawar et al., 2017).  
 
Mild symptoms such as unexplained weight loss and easy fatigue may remain 
unnoticed at an early stage of diabetes (Ford et al., 2010; Bansal, 2015). People do not 
consider this to be serious problems because, unlike many other diseases, the 
consequences of hyperglycaemia are not immediately manifested. People are not 
aware that damage began many years until the symptoms become noticeable. This is 
unfortunate because recognition of early symptoms can act as warning signs for people 
to immediately control the disease and prevent vascular complications. Moreover, 
prediabetic conditions, which are disregarded by many, may lead to a chronic 
progression of the disease.  
 
2.5 Diagnosis  
Some symptoms of diabetes may have remained unnoticed for many years. Hence, 
there are several ways to test for diabetes in laboratory. Each way usually needs to be 
repeated on a second day to confirm diagnosis of diabetes. Table 2.2 summarise the 





Table 2.2: The measurements, diagnosis value, and characteristic in diabetes 
diagnosis (Adapted from  Inzucchi, 2012; ADA, 2020) 
Measurement Diagnosis values Characteristics 




< 5.7% 5.7 – 6.4% ≥ 6.5% Testing should be 
performed in a 
laboratory using a 





standardised to the 
Diabetes Control and 
Complications Trial 
(DCCT) assay.  
 
The test reflects 
average blood glucose 









100 mg/dl – 
125 mg/dl 
≥ 126 mg/dl 
(7.0 
mmol/L) 
Fasting is defined as no 
caloric intake for at 









140 mg/dl – 
199 mg/dl 
≥ 200 mg/dl 
(11.1 
mmol/L)  
The test should be 
performed as described 
by the World Health 
Organization, using a 
glucose load containing 
the equivalent of 75 g 
anhydrous glucose 

















Random is defined as 
any time of the day, 
regardless of the 








2.6 Diabetes risk factors  
2.6.1 Genetic factors 
Genetic factors play important roles in the pathogenesis of diabetes. The human 
leukocyte antigen (HLA) complex accounts for the major genetic susceptibility to 
autoimmune disorder of T1DM (Noble and Valdes, 2011; Stenberg, 2015; Richardson 
et al., 2016). Polymorphism in HLA is strongly associated with the genetic 
susceptibility to T1DM. Some variants of the HLA-DQA1, HLA-DQB1, and HLA-
DRB1 genes increase the risk of developing T1DM. These genes provide instructions 
on how to make proteins that play a critical role in the immune system.  
 
Numerous mutations have been shown to reliably contribute to the risk in T2DM. 
Genes associated with T2DM risk including ATP binding cassette subfamily C 
member 8 (ABCC8), calpain 10 (CAPN10), glucose transporter 2 (GLUT2), glucagon 
receptor (GCGR) and transcription factor 7-like 2 (TCF7L2).  These genes control  
production of glucose, insulin production and regulation, and glucose level 
homeostasis in the body (Hansen, 2002; Kommoju and Reddy, 2011; J. Song et al., 
2017).  
 
GDM is thought to have strong heritability. Compared to pregnant women with normal 
glucose tolerance, GDM women have a significantly greater parental history of T2DM 
(Joham et al., 2014; Mukerji et al., 2020). Besides that, maturity-onset diabetes of the 
young 2 (MODY2) is an autosomal dominant form of MODY due to mutations in 
glucokinase (GCK) (Shaat et al., 2006; Gjesing et al., 2017; Rosik et al., 2020). GCK 
mutations cause pancreatic glucose sensing defects and result in lower insulin levels 
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during pregnancy. Apart from that, many studies have shown that the genes that play 
role in the occurrence of T2DM, exhibit strong connection to GDM risk. The genes 
such as TCF7L2, hepatocyte nuclear factor 4α (HNF4a), and glucokinase regulatory 
protein (GKRP) may increase the susceptibility to GDM ( Shaat et al., 2006; Freathy 
et al., 2010; Zhang et al., 2013; Gjesing et al., 2017).  
 
2.6.2 Environmental factors  
Environmental factors such as unhealthy diet, sedentary lifestyle, stress, and viral 
infection, are generally believed to account for the rapid global increase in diabetes 
prevalence and incidence in recent decades (Chan and Woo, 2010; Heianza and Qi, 
2017). Sedentary lifestyles and HFD consumption are generally behavioural factors 
conducive to the high prevalence of T2DM. Accumulation of fat from surplus calories 
and physical inactivity in the liver, muscles, and pancreas contributes to β-cell 
dysfunction and insulin resistance (Al-Goblan et al., 2014; Heianza and Qi, 2017). 
Long term of the unhealthy dietary and lifestyle promotes obesity or overweight, 
which increase the chance of developing T2DM.  
 
On the other hand, viral infection has been shown to trigger T1DM. Enteroviruses are 
a group of viruses that usually cause mild illnesses, like the common cold. Certain 
enterovirus strains, such as the coxsackievirus, enterovirus-D68, poliovirus, rotavirus, 
mumps virus have been specifically linked to T1DM especially in children (Coppieters 
et al., 2012; Craig et al., 2013; Beeck and Eizirik, 2016).  Children infected with 
enteroviruses may have no signs and symptoms of diabetes. In fact, they may exhibit 
symptoms of common cold like abdominal pain, diarrhoea, eye inflammation, 
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fevers, sore throat, vomiting, skin rash, and sharp pains in the rib muscle that mask 
the real disease to be left untreated. 
 
2.7 Diabetes complications  
2.7.1 Diabetic nephropathy 
Diabetic nephropathy is a serious kidney related complication that commonly present 
in patients suffering from both T1DM and T2DM. Over many years, poorly controlled 
diabetes can cause damage to blood vessels in the kidneys that delicate filtering 
system. This can lead to kidney damage and cause high blood pressure. High blood 
pressure can cause further kidney damage by increasing the pressure in the delicate 
filtering system of the kidneys. Diabetic nephropathy may gradually decrease kidney 
function and cause kidney failure over time (Teoh et al., 2010; Haneda et al., 2015; 
Pourghasem et al., 2015).  
 
Three major histologic changes occur in the glomeruli of people with diabetic 
nephropathy. First, mesangial expansion is directly induced by hyperglycaemia, 
possibly through increased matrix production or glycation of matrix proteins (Tervaert 
et al., 2010; Nguyen and Goldschmeding, 2019). Second, thickening of the glomerular 
basement membrane (GBM) occurs and the kidney function decreases as the injury 
worsens (John, 2016; Kriz et al., 2017). Third, glomerular sclerosis is caused by 
intraglomerular hypertension induced by dilatation of the afferent renal artery or from 
ischemic injury induced by hyaline narrowing of the vessels supplying the glomeruli 
(Kovesdy et al., 2017; Trevisan and Dodesini, 2017). Histological changes of the 
kidney lead to renal function failure and eventually become the major factors of 
dialysis and transplantation. 
17 
 
2.7.2 Non-alcoholic Fatty Liver Disease (NAFLD) 
Diabetes is closely associated with the rising prevalence and severity of non-alcoholic 
fatty liver disease (NAFLD) (Dietrich and Hellerbrand, 2014; Divella et al., 2019; 
Polyzos et al., 2019). This NAFLD refers to a wide spectrum of liver diseases ranging 
from the most common, fatty liver or steatosis, to advanced diseases such as non-
alcoholic steatohepatitis (NASH), NASH-related cirrhosis, and hepatocellular 
carcinoma (HCC).  NAFLD has a prevalence of 70% among T2DM patients. 
Particularly, the risk factors in T2DM such as overweight or obesity and insulin 
resistance have been strongly linked with NAFLD. 
 
Fatty liver or steatosis, the hallmark of NAFLD, occurs when accumulation of fat in 
the liver. While NASH is the liver inflammation caused by fat in the liver. On the other 
hand, cirrhosis is an irreversible and advanced scarring of the liver as a result of 
chronic inflammation of the liver (Dietrich and Hellerbrand, 2014; Polyzos et al., 
2019). 
 
All stages of NAFLD are now believed to be due to insulin resistance, a condition 
closely associated with obesity. Both BMI and obesity correlate with the degree of 
liver damage (Sharma et al., 2011; Dietrich and Hellerbrand, 2014). In fact, the greater 





2.7.3 Other complications 
There are many other complications associated with DM namely diabetic 
cardiomyopathy, diabetic retinopathy, and diabetic neuropathy (Jia et al., 2018; Yang 
et al., 2019; Preguiça et al., 2020).  
 
Diabetic cardiomyopathy is defined as the existence of abnormal cardiac morphology 
and performance of the myocardium in the absence of other confounding factors such 
as coronary artery disease (CAD), hypertension, and significant valvular disease 
(Marcinkiewicz et al., 2017; Jia et al., 2018). Both T1DM and T2DM patients are at 
risk of cardiomyopathy that leads to heart failure.  
 
Diabetic retinopathy can also develop in anyone who suffering from T1DM or T2DM. 
At first, diabetic retinopathy may cause no symptoms or only mild vision problems. 
However, it can eventually affect significant vision on a global scale (Duh et al., 2017; 
Liew et al., 2017; Wang and Lo, 2018). 
 
Diabetic neuropathy is another serious and common complication of T1DM and 
T2DM (Tesfaye, 2006; Said, 2013; Vinik et al., 2013; Mojto et al., 2019). It is a type 
of nerve damage caused by long-term hyperglycaemia. The condition usually develops 
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2.8 Diabetes management 
2.8.1 Non-pharmacology 
The role of non-pharmacological treatment in diabetes is well known for the 
prevention or reduction of diabetes. Exercise not only reduces hyperglycaemia, but 
also reduces insulin resistance by reducing obesity (Balducci et al., 2014; Kameswaran 
et al., 2014). Therapeutic diet also is helpful in management of diabetes. 
 
Kameswaran et al. (2014) reported that non-pharmacological interventions aimed at 
preventing T2DM including diet and physical activity. Lifestyle interventions appears 
to be at least as effective as drug treatment. Exercise is perceived to be beneficial for 
glycaemic control and weight loss in patient with T2DM. Physical activity not only 
improves blood glucose control in T2DM patients, but also reduces body weight and 
blood pressure. It improves the adverse lipid profile by reducing total cholesterol and 
low-density lipoprotein (LDL) cholesterol and increasing high-density lipoprotein 
(HDL) cholesterol. 
 
Nutritional interventions are important in achieving optimal blood glucose level 
control in patients with T2DM (Hansen, 2002; Kameswaran et al., 2014). Most patients 
with T2DM are overweight or obese and, therefore, weight loss due to dietary 
restriction of energy helps in diabetes management (Raveendran et al., 2018).  
Tuomilehto (2009) has shown that lifestyle management is highly effective in the 
prevention and early management of T2DM. This evidence of lifestyle modification 
in diabetes prevention is stronger than in most other multifactorial diseases. 
20 
 
Obesity, physical inactivity, and unbalanced diet are well known to be the major risk 
factors for diabetes (Lin and Sun, 2010; Ng et al., 2010). In people genetically 
predisposed to the disease, the likehood of developing T2DM diabetes is high once 
they are exposed to unhealthy lifestyles. 
 
2.8.2 Pharmacological 
Pharmacologic approaches must be based on the patient characteristics, the level of 
glucose control and cost considerations. A combination of different oral agents may 
be useful for controlling hyperglycaemia before insulin therapy becomes necessary. 
Table 2.3 summarises the class, characteristics, and generic, and brand names of anti-

















Table 2.3: The class, characteristics, and generic name, and brand name of anti-
diabetic drugs (Adapted from Surya et al., 2014; Marín-Peñalver et al., 
2016) 












Biguanides Reduce the amount 








without making it 










peptides 1 (GLP-1) 
agonist 










Meglitinides Stimulate the 
pancreas to release 


















Sulfonylureas Stimulate the 
























2.9 Etlingera elatior (Bunga Kantan)  
2.9.1 General description  
Etlingera elatior or torch ginger is one of the most popular plants belongs to genus 
Etlingera in the ginger family known as Zingiberaceae. The genus Etlingera brings 
many beneficial products including dyes, foods, fragrance, essential oils, male 
aesthetics, medicine, and spices (Jaafar et al., 2007). 
 
In Malaysia, E. elatior, also well known as Bunga kantan, is traditionally used by local 
folks for food flavouring and medicinal purposes. Young shoots and buds of E. elatior 
are consumed raw as fresh vegetables or ulam (Ghasemzadeh et al., 2015). Besides 
that, its flower (Figure 2.1) is commonly used as condiment for many iconic Malaysian 
dishes, for example asam laksa, nyonya laksa, asam pedas, nasi kerabu, and nasi ulam.   
 
 
Figure 2.1: The flower of E. elatior 
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Traditionally, the local folks believe that daily intake of raw inflorescence of E. elatior 
can reduce diabetes and hypertension (Jeevani et al., 2011). The E. elatior flower 
methanol extract is used as traditional remedy for stomach aches or headache and 
applied externally to relieve itching (Lachumy et al., 2010). Apart from that, the 
decoction of its leaves is traditionally used in wound healing, while the fruits are used 
to treat earache (Chan et al., 2011; Jackie et al., 2011). Consumption of E. elatior 
inflorescence along with bitter leaves (Vernonia amygdalina) is thought to relieve 
flatulence in postpartum women (Mai et al., 2009; Wijekoon et al., 2011). In addition, 
the mixture of E. elatior leaves with other aromatic herbs are used for bathing to 
remove body odour especially among women  (Chan et al., 2011).   
 
2.9.2 Phytochemistry  
In recent years, the phytochemical in E. elatior has received increasing interest due to 
their importance for biological properties. Phytochemical screening of E. elatior 
inflorescence has been reported to be rich in biochemical compounds such as 
anthocyanin, flavonoid, phenolic, saponins, tannins, and terpenoids contents 
(Lachumy et al., 2010; Wijekoon et al., 2011). In E. elatior leaves, chlorogenic acid, 
flavonoids of kaempferol 3-glucuronide, quercetin 3-glucuronide, quercetin 3-
glucoside, and quercetin 3-rhamnoside have been reported. Meanwhile, 
diarylheptanoids, labdane, diterpenoids and steroids have been isolated from E. elatior 
rhizomes (Habsah et al., 2000; Ghasemzadeh et al., 2015). Its inflorescence has also 
been reported to contain a significant amount of carbohydrate, crude protein, fibre, 





2.9.3 Potential therapeutic values  
Traditionally, it is believed that the daily intake of raw inflorescence can reduce 
diabetes and hypertension diseases. Some studies have proven that E. elatior rhizomes 
have significantly exhibited anti α-glucosidase and anti α-amylase, antioxidant, anti-
inflammatory properties  (Ud-Daula et al., 2016; Juwita et al., 2018; Anzian et al., 
2020) . In addition, various studies have shown that the inflorescence of E. elatior has 
many other biological properties such as anti-microbial, anti-cancer, anti-proliferative, 
cytotoxic activity and antioxidant (Chan et al., 2011; Ghasemzadeh et al., 2015). 
Researches conducted by  Lachumy et al. (2010) and Susanti et al. (2013) proved that 
flower extract of E. elatior exhibit antibacterial activities against Bacillus cereus and 
Staphylococcus aureus, and antifungal activity against Candida albican and 
Cryptococcus neoformans. Their studies claimed that Gram positive bacteria were 
more susceptible toward the E. elatior flower extract compared to that of Gram 
negative bacteria. Apart from that, the extract of E. elatior has also showed promising 
cytotoxic and anti-tumour promoting activity (Ghasemzadeh et al., 2015; Juwita et al., 
2018).  
 
 
 
 
 
 
 
